Logo image of SION

SIONNA THERAPEUTICS INC (SION) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:SION - US8294011080 - Common Stock

44.38 USD
+0.72 (+1.65%)
Last: 11/24/2025, 5:28:27 PM
Fundamental Rating

3

SION gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 533 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for SION as it has an excellent financial health rating, but there are worries on the profitability. SION does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

SION had negative earnings in the past year.
SION had a negative operating cash flow in the past year.
SION Yearly Net Income VS EBIT VS OCF VS FCFSION Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2022 2023 2024 -20M -40M -60M

1.2 Ratios

SION has a better Return On Assets (-20.83%) than 75.61% of its industry peers.
SION has a better Return On Equity (-21.97%) than 83.11% of its industry peers.
Industry RankSector Rank
ROA -20.83%
ROE -21.97%
ROIC N/A
ROA(3y)-56.75%
ROA(5y)N/A
ROE(3y)-75.41%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
SION Yearly ROA, ROE, ROICSION Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2022 2023 2024 -20 -40 -60 -80 -100

1.3 Margins

SION does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SION Yearly Profit, Operating, Gross MarginsSION Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2022 2023 2024

More info and screens

9

2. Health

2.1 Basic Checks

The number of shares outstanding for SION remains at a similar level compared to 1 year ago.
SION has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
SION Yearly Shares OutstandingSION Yearly Shares OutstandingYearly Shares Outstanding 2022 2023 2024 10M 20M 30M 40M
SION Yearly Total Debt VS Total AssetsSION Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2022 2023 2024 50M 100M 150M

2.2 Solvency

SION has an Altman-Z score of 64.76. This indicates that SION is financially healthy and has little risk of bankruptcy at the moment.
SION has a Altman-Z score of 64.76. This is amongst the best in the industry. SION outperforms 97.94% of its industry peers.
SION has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 64.76
ROIC/WACCN/A
WACCN/A
SION Yearly LT Debt VS Equity VS FCFSION Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2022 2023 2024 0 50M -50M 100M 150M

2.3 Liquidity

SION has a Current Ratio of 25.61. This indicates that SION is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 25.61, SION belongs to the top of the industry, outperforming 97.75% of the companies in the same industry.
A Quick Ratio of 25.61 indicates that SION has no problem at all paying its short term obligations.
With an excellent Quick ratio value of 25.61, SION belongs to the best of the industry, outperforming 97.75% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 25.61
Quick Ratio 25.61
SION Yearly Current Assets VS Current LiabilitesSION Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2022 2023 2024 50M 100M 150M

More info and screens

0

3. Growth

3.1 Past

SION shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -30.53%.
EPS 1Y (TTM)-30.53%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%57.5%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

SION is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -7.37% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y7.45%
EPS Next 2Y-1.03%
EPS Next 3Y-9.68%
EPS Next 5Y-7.37%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
SION Yearly Revenue VS EstimatesSION Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M
SION Yearly EPS VS EstimatesSION Yearly EPS VS EstimatesYearly EPS VS Estimates 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 1 -1 -2 -3

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for SION. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SION. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SION Price Earnings VS Forward Price EarningsSION Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SION Per share dataSION EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4 6

4.3 Compensation for Growth

A cheap valuation may be justified as SION's earnings are expected to decrease with -9.68% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-1.03%
EPS Next 3Y-9.68%

More info and screens

0

5. Dividend

5.1 Amount

SION does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SIONNA THERAPEUTICS INC

NASDAQ:SION (11/24/2025, 5:28:27 PM)

44.38

+0.72 (+1.65%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-05 2025-11-05/bmo
Earnings (Next)03-16 2026-03-16
Inst Owners71.55%
Inst Owner Change-1.32%
Ins Owners1.39%
Ins Owner Change-2.43%
Market Cap1.96B
Revenue(TTM)N/A
Net Income(TTM)-70.68M
Analysts85
Price Target41.14 (-7.3%)
Short Float %10.09%
Short Ratio9.84
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)17.23%
Min EPS beat(2)6.88%
Max EPS beat(2)27.57%
EPS beat(4)2
Avg EPS beat(4)-119.42%
Min EPS beat(4)-476.3%
Max EPS beat(4)27.57%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)6.14%
PT rev (3m)4.76%
EPS NQ rev (1m)1.58%
EPS NQ rev (3m)8.28%
EPS NY rev (1m)0%
EPS NY rev (3m)2.99%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 6.09
P/tB 6.09
EV/EBITDA N/A
EPS(TTM)-4.87
EYN/A
EPS(NY)-2.26
Fwd EYN/A
FCF(TTM)-1.4
FCFYN/A
OCF(TTM)-1.39
OCFYN/A
SpS0
BVpS7.29
TBVpS7.29
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -20.83%
ROE -21.97%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-56.75%
ROA(5y)N/A
ROE(3y)-75.41%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 30.21%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 25.61
Quick Ratio 25.61
Altman-Z 64.76
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)577.18%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-30.53%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%57.5%
EPS Next Y7.45%
EPS Next 2Y-1.03%
EPS Next 3Y-9.68%
EPS Next 5Y-7.37%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-40.18%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-23.28%
EBIT Next 3Y-27.27%
EBIT Next 5YN/A
FCF growth 1Y-17.85%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-20.8%
OCF growth 3YN/A
OCF growth 5YN/A

SIONNA THERAPEUTICS INC / SION FAQ

What is the ChartMill fundamental rating of SIONNA THERAPEUTICS INC (SION) stock?

ChartMill assigns a fundamental rating of 3 / 10 to SION.


Can you provide the valuation status for SIONNA THERAPEUTICS INC?

ChartMill assigns a valuation rating of 0 / 10 to SIONNA THERAPEUTICS INC (SION). This can be considered as Overvalued.


Can you provide the profitability details for SIONNA THERAPEUTICS INC?

SIONNA THERAPEUTICS INC (SION) has a profitability rating of 1 / 10.


Can you provide the financial health for SION stock?

The financial health rating of SIONNA THERAPEUTICS INC (SION) is 9 / 10.


What is the earnings growth outlook for SIONNA THERAPEUTICS INC?

The Earnings per Share (EPS) of SIONNA THERAPEUTICS INC (SION) is expected to grow by 7.45% in the next year.